Corindus Vascular Robotics develops and manufactures robotic-assisted systems designed to enhance the precision and safety of catheter-based vascular interventions. Its solutions enable interventional cardiologists and radiologists to remotely manipulate guidewires, balloons, stents and other devices during percutaneous procedures, while reducing radiation exposure and physical strain on clinical staff. By integrating robotics with imaging and control software, the company aims to improve procedural consistency and patient outcomes in complex vascular treatments.
The company’s flagship offering, the CorPath System, has received regulatory clearances for a range of applications in both coronary and peripheral vascular interventions. The platform features a single-use disposable cassette and an operator console that can be positioned several feet from the patient table, allowing clinicians to carry out precise device movements with sub-millimeter accuracy. Subsequent iterations, such as the CorPath GRX System, have introduced expanded compatibility with interventional devices and software enhancements designed to streamline procedure workflows.
Founded in 2002 and headquartered in Waltham, Massachusetts, Corindus Vascular Robotics established itself as a pioneer in vascular robotics and completed its initial public offering on the NYSE American under the ticker CVRS. In 2019, the company was acquired by Siemens Healthineers, becoming part of its broader portfolio of minimally invasive treatment solutions. This integration has enabled Corindus to leverage Siemens’ global infrastructure, R&D resources and clinical network to accelerate the adoption of robotic-assisted interventions.
Corindus serves hospitals and catheterization laboratories across North America, Europe, Asia Pacific and select emerging markets. As a business unit within Siemens Healthineers, its management and development efforts are aligned with the parent company’s commitment to driving innovation in image-guided therapies. The continued rollout of robotic platforms underscores the company’s strategic focus on transforming interventional procedures through automation and digital connectivity.
AI Generated. May Contain Errors.
Free CVRS Stock Alerts